Search

Objective: To determine oxytetracycline concentrations in plasma and in fluid from Corynebacterium pseudotuberculosis (CPT)-inoculated tissue chambers (used as experimental abscess models) and uninoculated (control) tissue chambers in sheep after IM or local administration of the drug and to investigate whether CPT growth was reduced or eliminated by these treatments., Animals: 10 clinically normal female sheep., Procedures: Sterile tissue chambers were surgically implanted in both paralumbar fossae of each sheep; ≥ 2 weeks later (day -6), 1 randomly selected chamber was inoculated with CPT, and the opposite chamber was injected with sterile growth medium. Sheep received oxytetracycline IM (n = 5) or by percutaneous injection into CPT-inoculated (4) or uninoculated (1) chambers on day 0. Tissue fluid from each chamber and venous blood samples for plasma collection were obtained at predetermined times over 6 days for bacterial counts (tissue chambers) and analysis of oxytetracycline concentrations (tissue chambers and plasma). Sheep were euthanized on day 6. Regional lymph nodes were collected bilaterally from each sheep for culture., Results: Measurable concentrations of oxytetracycline were present in each chamber throughout the study, regardless of administration route or presence of CPT. No CPT growth was detected after the 48-hour time point in inoculated chambers injected with oxytetracycline; however, CPT was isolated from all inoculated chambers throughout the study after IM drug administration. One regional lymph node (ipsilateral to a CPT-inoculated, oxytetracycline-injected chamber with no CPT growth after 48 hours) was culture positive for CPT., Conclusions and Clinical Relevance: Intralesional administration of oxytetracycline may eliminate growth of CPT locally, but complete elimination of the organism remains difficult.

Objective: To determine the serologic and bacteriologic culture prevalence of Corynebacterium pseudotuberculosis infection in sheep and goats and the value of such assays for prediction of future development of caseous lymphadenitis (CL)., Design: Observational study., Animals: 919 goats and sheep in 3 herds in southwest Texas., Procedures: During an initial evaluation, serologic and bacteriologic culture status for CL was determined for all animals. Subsequently, animals were evaluated every 6 months for a 13-month period to detect external CL lesions. Affected animals in 2 herds were treated with tulathromycin or a control treatment; affected animals in 1 herd were culled. The value of assays for prediction of future development of CL lesions was determined., Results: The serologic prevalence of CL in herds at the start of the study ranged from 7.52% to 69.54%. The bacteriologic culture prevalence of CL ranged from 0% to 6.12% at the start of the study and 0% to 9.56% at the end of the study. Synergistic hemolysin inhibition results were poor predictors of future development of CL lesions in animals during the study period; however, animals with positive bacteriologic culture results for CL were more likely to develop lesions in the future than were animals with negative bacteriologic culture results., Conclusions and Clinical Relevance: Caseous lymphadenitis was detected in animals in this study despite prior management of affected animals in herds via culling. Use of a synergistic hemolysin inhibition test for management of CL may cause unnecessary culling of animals; treatment might allow retention of genetically valuable CL-affected animals in a herd without substantially increasing the prevalence of CL.

This article reviews laws and regulations related to drug use in sheep and goats, with special reference to the United States. The discussion includes drug licensing procedures, legalities of extralabel drug use, withdrawal time estimation, and residues in sheep and goat tissues; it refers also to regulations related to organic production, dairy production, and compounding. Canadian and European regulations are mentioned. Veterinarians working with sheep and goats must be familiar with regulations governing use of drugs, to prevent legal action, fulfill their fiduciary responsibility to producers, and help protect and provide for a wholesome and safe food supply., (Copyright © 2011 Elsevier Inc. All rights reserved.)

Objective: To compare the effectiveness of 3 treatment regimens for small ruminants with caseous lymphadenitis., Design: Randomized clinical trial., Animals: 44 client-owned sheep and goats., Procedures: Aspirates were obtained from 48 lesions of 44 enrolled animals and submitted for bacterial culture. Animals were randomly assigned to 1 of 3 treatment groups. Treatment for group A (n = 15 lesions) consisted of opening, draining, and flushing the lesions and SC administration of procaine penicillin G. Treatment for group B (n = 15 lesions) consisted of closed-system lavage and intralesional administration of tulathromycin. Treatment for group C (n = 18 lesions) consisted of closed-system lavage and SC administration of tulathromycin. All animals were reexamined approximately 1 month after treatment, unless treatment failure was detected prior to that time., Results: 43 animals with lesions had positive results (Corynebacterium pseudotuberculosis) for bacterial culture. Proportions of lesions that had resolution of infection by 1 month after treatment did not differ significantly among the treatment groups (group A, 13/14 [92.9%]; 95% confidence interval [CI], 69.5% to 99.6%; group B, 10/12 [83.3%]; 95% CI, 54.9% to 97.1%; and group C, 14/17 [82.4%]; 95% CI, 59.1% to 95.3%)., Conclusions and Clinical Relevance: Acceptable alternatives to opening, draining, and flushing of lesions may exist for treatment of sheep and goats with caseous lymphadenitis. Use of tulathromycin and penicillin in this study constituted extralabel drug use, which would require extended withholding times before milk or meat of treated sheep and goats can be sold for human consumption.

The small ruminant practitioner has a small arsenal of approved drugs in the United States, so the practitioner must be familiar with the laws and regulations related to extra label use. Drugs can be used extra label in food animals only under specific circumstances and can be used only for therapeutic purposes. Drugs that are illegal in small ruminants include chloramphenicol; clenbuterol; diethylstilbestrol; dimetridazole, ipranidazole, and other nitroimidazoles such as metronidazole; dipyrone; fluoroquinolones; glycopeptides; nitrofurans; furazolidone; and extra label use of medication in feed. It is also illegal to use any drug that results in residues above established tolerances or safe levels.